Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404573 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT00404573: Completed Phase 2 study, sponsored by Forest Laboratories.
NCT00404573 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 375 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (182% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00404573, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
Interventions
- DRUG RGH-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2006-11 |
| Phase | Phase 2 |
What the finished NCT00404573 record still lists
NCT00404573 is an interventional study that assigns participants to a tested intervention. The registered 375 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (182% higher).
The record links to 0 conditions, and to 1 intervention - of which RGH-188 is the first listed.
NCT00404573 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00404573 about?
NCT00404573 is a clinical study titled "Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia". This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three ...
What is the current status of trial NCT00404573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00404573?
The interventions under investigation include: RGH-188 (DRUG).
Who is sponsoring clinical trial NCT00404573?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00404573's enrollment target sits among peer trials
375 116th of 2000 higher than 1,883 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03686124 · 375 participants · Phase 1
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- NCT04059172 · 375 participants · Early Phase 1
Efficacy of Combined Ibuprofen and Acetaminophen Therapy Versus Ibuprofen Alone Versus Placebo Alone for Pain Management
- NCT04134923 · 375 participants
Imaging Biomarkers in Preclinical and Symptomatic AD
- NCT04569747 · 375 participants · Phase 2
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia